Literature DB >> 31665718

Landscape of Immune-Related Pneumonitis in Cancer Patients with Asthma Being Treated with Immune Checkpoint Blockade.

Jessica Galant-Swafford1, Adrien Troesch2, Lisa Tran3, Ashley Weaver3, Taylor A Doherty4, Sandip Pravin Patel3.   

Abstract

INTRODUCTION: Predicting the factors that increase the risk of immune-related pneumonitis, a potentially life-threatening complication of treatment with immune checkpoint inhibitors for cancer, is a clinical challenge. Baseline clinical factors such as asthma may portend the development of pneumonitis due to pre-existing airway inflammation prior to immunotherapy.
OBJECTIVE: The purpose of the study was to investigate whether a prior diagnosis of asthma is associated with an increased risk of immune-related pneumonitis in patients undergoing cancer immunotherapy.
METHODS: Patients at the Moores Cancer Center at UC San Diego Health undergoing immunotherapy were identified on an IRB-approved protocol. Clinical charts were reviewed for asthma documented in the medical records and CT scans were reviewed during and after treatment. Pneumonitis was defined as the onset of new pulmonary symptoms with characteristic imaging findings during or after a patient's first course of immunotherapy that could not be readily explained as infection or a progression of malignancy. It was graded according to the Common Terminology Criteria for Adverse Events.
RESULTS: A total of 187 patients were included. A diagnosis of asthma was found in the records of 26 cases (13.9%). Pneumonitis was found in 10 cases (5.35%); 50% were grade 2 and 50% were grade 3-4. Two of the grade 3-4 cases (40%) occurred in patients with non-small-cell lung cancer. Three patients with asthma developed pneumonitis (11.5% of patients with asthma), all grade 3-4. Only 28.6% of the non-asthma-pneumonitis cases were grade 3-4. All (100%) of the asthma-pneumonitis patients were former smokers, while 71.4% of the non-asthma-pneumonitis patients were former smokers.
CONCLUSION: A history of asthma may be associated with a higher grade of pneumonitis if it develops, and a history of smoking may augment this relationship.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Asthma; Checkpoint inhibitors; Immune-related adverse events; Immunotherapy; Pneumonitis

Mesh:

Substances:

Year:  2019        PMID: 31665718      PMCID: PMC7292032          DOI: 10.1159/000503566

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  23 in total

Review 1.  Role of PD-L1 and PD-L2 in allergic diseases and asthma.

Authors:  A K Singh; P Stock; O Akbari
Journal:  Allergy       Date:  2010-08-17       Impact factor: 13.146

2.  PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.

Authors:  Mizuki Nishino; Nikhil H Ramaiya; Mark M Awad; Lynette M Sholl; Jennifer A Maattala; Myriam Taibi; Hiroto Hatabu; Patrick A Ott; Philippe F Armand; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2016-08-17       Impact factor: 12.531

Review 3.  Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Authors:  Monica Khunger; Sagar Rakshit; Vinay Pasupuleti; Adrian V Hernandez; Peter Mazzone; James Stevenson; Nathan A Pennell; Vamsidhar Velcheti
Journal:  Chest       Date:  2017-05-10       Impact factor: 9.410

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism.

Authors:  Koichiro Matsumoto; Hiromasa Inoue; Takako Nakano; Miyuki Tsuda; Yuki Yoshiura; Satoru Fukuyama; Fumihiko Tsushima; Tomoaki Hoshino; Hisamichi Aizawa; Hisaya Akiba; Drew Pardoll; Nobuyuki Hara; Hideo Yagita; Miyuki Azuma; Yoichi Nakanishi
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

Review 6.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

Review 7.  Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Authors:  Mizuki Nishino; Hiroto Hatabu; Lynette M Sholl; Nikhil H Ramaiya
Journal:  Radiographics       Date:  2017 Sep-Oct       Impact factor: 5.333

8.  PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.

Authors:  O Akbari; P Stock; A K Singh; V Lombardi; W-L Lee; G J Freeman; A H Sharpe; D T Umetsu; R H Dekruyff
Journal:  Mucosal Immunol       Date:  2009-09-09       Impact factor: 7.313

Review 9.  Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Authors:  Sarah Chuzi; Fabio Tavora; Marcelo Cruz; Ricardo Costa; Young Kwang Chae; Benedito A Carneiro; Francis J Giles
Journal:  Cancer Manag Res       Date:  2017-06-14       Impact factor: 3.989

10.  Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.

Authors:  Naoya Yamazaki; Yoshio Kiyohara; Hisashi Uhara; Hajime Iizuka; Jiro Uehara; Fujio Otsuka; Yasuhiro Fujisawa; Tatsuya Takenouchi; Taiki Isei; Keiji Iwatsuki; Hiroshi Uchi; Hironobu Ihn; Hironobu Minami; Hideaki Tahara
Journal:  Cancer Sci       Date:  2017-05-11       Impact factor: 6.716

View more
  4 in total

Review 1.  Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management.

Authors:  Seohyun Kim; Jeong Uk Lim
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

Review 2.  The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.

Authors:  Xiaoyang Zhai; Jian Zhang; Yaru Tian; Ji Li; Wang Jing; Hongbo Guo; Hui Zhu
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

Review 3.  Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer.

Authors:  Anqi Zhang; Fuyuan Yang; Lei Gao; Xiaoyan Shi; Jiyuan Yang
Journal:  Cancer Manag Res       Date:  2022-08-13       Impact factor: 3.602

4.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.